Last reviewed · How we verify
hrr gene mutated metastatic castration resistant prostate cancer mcrpc
Approved treatments
Clinical guidelines
- FDA label — any
TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- hrr gene mutated metastatic castration resistant prostate cancer mcrpc patent landscape — cliff calendar, originator estates, attackable patents
- hrr gene mutated metastatic castration resistant prostate cancer mcrpc treatment landscape brief
- hrr gene mutated metastatic castration resistant prostate cancer mcrpc treatment updates RSS
Frequently asked questions about hrr gene mutated metastatic castration resistant prostate cancer mcrpc
What are the treatment guidelines for hrr gene mutated metastatic castration resistant prostate cancer mcrpc?
FDA label publishes guidelines for hrr gene mutated metastatic castration resistant prostate cancer mcrpc. 1 guideline references tracked.
Related
- Treatment landscape: hrr gene mutated metastatic castration resistant prostate cancer mcrpc patent cliff · hrr gene mutated metastatic castration resistant prostate cancer mcrpc CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing